Pharma Business - May 3, 2016
AZ’s first quarter performance
AstraZeneca’s Q1 2016 results include a total revenue growth by 5 %, driven by a significant increase in externalization Revenue and the results are in line with expectations. The company’s core R&D costs increased by 15%, reflecting recent acquisitions and the Core R&D costs declined versus Q4 2015. The core SG&A costs fell by 6% and […]
Agreement - April 27, 2016
AZ enters agreement with Ironwood
AstraZeneca has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of hyperuricemia associated with uncontrolled gout. Under the terms of the agreement, Ironwood […]
Drug Development Pharma - April 22, 2016
AZ launches integrated genomics approach
AstraZeneca and its global biologics research and development arm, MedImmune, has announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline. The initiative involves for example a new collaboration with the Institute for Molecular Medicine in Finland. The initiative includes new collaborations with Human Longevity, US, the Wellcome […]
Acquisition - April 19, 2016
AZ explore potential takeover of Medivation
The Sunday Times reports that AstraZeneca has held “internal talks” regarding a potential bid for Medivation, but the company has not yet made a formal proposal, reported the magazine and citing unnamed sources. According to the newspaper, AstraZeneca has been tracking Medivation for the past six months, while a senior healthcare banker is quoted as saying […]
Clinical Trials - April 13, 2016
AZ, Eli Lilly continue with AMARANTH clinical trial
AstraZeneca and Eli Lilly and Company announces that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial. The AMARANTH independent data monitoring committee recommended the study continue […]
Pharma Business - March 29, 2016
AZ’s Tagrisso approved in Japan
The Japanese Ministry of Health, Labour and Welfare has approved Tagrisso (osimertinib, AZD9291) 80mg once-daily tablets for the treatment of patients with epidermal growth factor receptor (EGFR) T790M mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC) that is resistant to EGFR tyrosine kinase inhibitor (TKI) therapy. Sean Bohen, Executive Vice President, Global Medicines Development […]
